Growth Hormone

CJC-1295

Follow to see evidence and UK status changes for this compound in your updates.

Rather than taking growth hormone directly, this tries to boost your own supply. People turn to it for recovery, sleep and body shape as natural hormone levels fall with age. Almost always paired with Ipamorelin, and mostly found through private UK clinics rather than the NHS.

GH-releasing , almost always paired with Ipamorelin, used for recovery, sleep and body composition.

How well studied

Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied

BHow well studiedSome good studies

Tested in people, but in smaller or fewer studies. A decent picture, just less certain.

UK status

How you could legitimately come across it here, if at all

UK statusNo UK licence; private clinic route described

There is no UK licence for this. Our notes describe supply happening through the unlicensed-medicines route, where an individual prescriber takes personal responsibility. Whether any particular clinic can supply it to you is not something this app can confirm.

Evidence strength and UK regulatory status answer different questions.

Overview

How it works

Your pituitary gland, a small hormone-control centre in the brain, gets nudged into releasing longer, stronger bursts of growth hormone.

Extends the natural pulse of growth release from the pituitary, raising GH/ over time.

Reported benefits

  • Randomised human pharmacology studies show sustained increases in GH and IGF-1 after CJC-1295 DAC
  • Clinical benefits for recovery, sleep, muscle gain or fat loss have not been established in robust outcome trials

Who it's typically used for

Training recovery, sleep quality, body composition support

Timeline to results

Human studies establish hormone changes, not a validated timeline for recovery, sleep or body-composition benefits.

Safety & UK access

Dosage

No established human dose

No established human dose. The controlled human data for CJC-1295 DAC characterise its pharmacokinetics and hormone response, not a therapeutic regimen, and non-DAC CJC-1295 or Mod GRF 1-29 products behave differently again.

Side effects

  • Injection site reactionsreported in early clinical pharmacology studies of CJC-1295 DAC in healthy adults
  • Water retentionreported; not quantified for this compound
  • Raised IGF-1expected pharmacological effect; long-term consequences in healthy adults unknown

Getting it in the UK

UK statusNo UK licence; private clinic route described

There is no UK licence for this. Our notes describe supply happening through the unlicensed-medicines route, where an individual prescriber takes personal responsibility. Whether any particular clinic can supply it to you is not something this app can confirm.

Where it turns up

  • Specialist unlicensed supply
  • Private prescription

Not authorised as a UK medicine. Our existing notes describe private clinics supplying it through the unlicensed-medicines route, which relies on an individual prescriber taking responsibility. Treat availability as clinic-specific rather than settled.

Not MHRA-licensed; prescribable by a private UK doctor via the unlicensed-medicines route, and a standard private-clinic pairing

MHRA: the UK regulator that assesses whether a medicine is safe and works before it can be authorised for use here. Something not being MHRA-licensed does not automatically mean it is illegal, and it does not mean it is safe.

This is background information about UK regulation, not advice about what you can or should obtain.

Evidence & sources

Why this rating?

The A to D rating shown above comes from our earlier editorial review and is still waiting to be migrated into the structured review record below. That is a gap in our record-keeping, not a sign the rating is wrong.

Evidence fingerprint

No route and indication scope has been published for this profile yet, so no fingerprint is shown.

Sources

Structured source audit not yet published for this profile. The references behind this page are being catalogued one compound at a time, and this one has not been through that process yet.

Content freshness

Last reviewed
24 Sept 2026
Regulatory status last checked
21 Aug 2026